Target intelligence / Profile preview

Hemoglobin subunit alpha 2 (HBA2)

Target
HBA2
Molecular classification
Other (Globin protein, oxygen carrier)
01

Overview

Hemoglobin subunit alpha 2 is a globin protein encoded by the HBA2 gene on chromosome 16 and constitutes one of the two nearly identical alpha-globin gene products (together with HBA1). Two alpha subunits (from HBA1 and HBA2) combine with two beta subunits to form hemoglobin A (HbA), the most prevalent form of adult hemoglobin, responsible for oxygen transport in red blood cells. Alpha-globin also partners with gamma- or delta-globin in fetal and minor adult hemoglobins. Mutations or deletions in HBA2 (and/or HBA1) lead to various forms of alpha-thalassemia, ranging from asymptomatic carriers to fatal hydrops fetalis, depending on the number and kind of affected alleles. The primary biological function of alpha-globin is high-efficiency oxygen binding and delivery, with loss-of-function variants resulting in severe systemic hypoxia and anemia

Other names
Hemoglobin subunit alphaHemoglobin alpha chainAlpha-globinAlpha 2 globinHBA-T2HBHHBA1HemopressinECYT7HBA_HUMANhemoglobin, alpha 2mutant hemoglobin alpha 2 globin chainhemoglobin-alpha locus 2major alpha-globin locus
02

Mechanism of action

Not applicable (HBA2 is not a direct therapeutic drug target but is impacted by drugs modifying hemoglobin’s oxygen affinity, though not specifically or selectively through HBA2)

03

Biological functions

Oxygen transportIron ion bindingCellular response to hypoxia
04

Disease associations

Hemoglobinopathies (e.g., Alpha-thalassemia, Hemoglobin H disease)AnemiaHydrops fetalis
05

Safety considerations

Not directly drug-targeted; concerns relate to genetic deficiencies rather than pharmacological intervention (e.g., alpha-thalassemia syndromes cause severe anemia and fetal hydrops)
06

Interacting drugs

No classic direct pharmaceutical drugs target HBA2 for therapeutic manipulation; however, hemoglobin (and thus HBA2) may interact with blood substitutes, oxygen therapeutics, and hemoglobin modifiers (e.g., Voxelotor for sickle cell disease, but not directly selective for HBA2.)
07

Biomarkers

Percentage of HbA, HbA2, and HbF in hemoglobin electrophoresis (used in diagnosis of thalassemias and hemoglobinopathies)HBA2 gene mutation analysis for diagnostic purposes

Beyond the preview

Go deeper on Hemoglobin subunit alpha 2 (HBA2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemoglobin subunit alpha 2 (HBA2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call